Abstract YO18
Case summary
Case Details - A 47-year-old female, a known case of multicentric Glioblastoma multiforme (grade four) who had received concurrent chemoradiotherapy followed by palliative Temozolomide on tapering doses of Levetiracetam and had been commenced on Phenytoin presented (during the peak of the second wave of Pandemic) with complaints of new-onset maculopapular lesions involving legs, arms, and lower back. She subsequently developed a worsening Rash with the development of vesico-bullous lesions, oral mucosal lesions, acral involvement, and systemic symptoms (Fever) 2 days later. Arrangements were made to obtain a Tele Dermatology consult (from a Private setting) following which a diagnosis of SJS TENS Overlap was made. A consult with the Medical Oncology department was sought in order to provide ICU admission which was refused. She was subsequently admitted under Palliative Medicine after obtaining high-risk consent. Her lesions regressed with supportive management comprising Cyclosporin, and intravenous antibiotics, however, her general condition deteriorated. She was discharged as she had expressed a wish to meet her mother (at home). However, she was unable to obtain a fitness for Air travel. She was re-admitted and re-started on supportive treatment (symptom-directed medications via intravenous route). A subcutaneous line was inserted in the anterior chest wall and pre-filled syringes containing essential pain medication, anti-seizure medication (sc bolus levetiracetam), and dexamethasone for three days were provided to the Patient’s husband who had volunteered to take her back home via Train.
Discussion - Important Issues included Logistical - Lack of infrastructure, Medical - use of boluses of subcutaneous medication at end of life (without syringe drivers).
Conclusion - Practical Issues related to Travel, Finances, and Continuity of care may assume more importance than Spirituality underlining the importance of formulating a comprehensive management plan most suited to the Patient and their Family members.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06